Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma.

IF 2.3 3区医学 Q1 OTORHINOLARYNGOLOGY

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2024-08-12 DOI:10.1002/hed.27917

Zikun Yu, Qin Wang, Zimeng Wang, Sihan Liu, Tianliang Xia, Chongyang Duan, Youping Liu, Xi Ding, Siyuan Chen, Tao Yu, Rui You, Mingyuan Chen, Peiyu Huang

{"title":"Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma.","authors":"Zikun Yu, Qin Wang, Zimeng Wang, Sihan Liu, Tianliang Xia, Chongyang Duan, Youping Liu, Xi Ding, Siyuan Chen, Tao Yu, Rui You, Mingyuan Chen, Peiyu Huang","doi":"10.1002/hed.27917","DOIUrl":null,"url":null,"abstract":"Background: Effective biomarkers for assessing anti-PD-1/PD-L1 therapy efficacy in patients with nasopharyngeal carcinoma (NPC) are still lacking. The human gut microbiota has been shown to influence clinical response to anti-PD-1/PD-L1 therapy in many cancers. However, the relationship between the gut microbiota and the efficacy of immunotherapy in patients with nasopharyngeal carcinoma has not been determined.Methods: We conducted a prospective study in which fecal and blood samples from patients with NPC were subjected to 16S rDNA sequencing and survival analysis. To investigate potential differences in the gut microbiome between these groups and to identify potential biomarkers indicative of immunotherapy efficacy, patients were categorized into two groups according to their clinical response to immunotherapy, the responder group (R group) and the non-responder group (NR group). Progression-free survival (PFS) between these subgroups was analyzed using Kaplan-Meier survival analysis with the log-rank test. Additionally, we performed univariate and multivariate analyses to evaluate prognostic factors. Finally, we carried out non-targeted metabolomics to examine the metabolic effects associated with the identified microbiome.Results: Our 16S rDNA sequencing results showed that the abundance of Lachnoclostridium was higher in the NR group than in the R group (p = 0.003), and alpha diversity analysis showed that the abundance of microbiota in the NR group was higher than that in the R group (p = 0.050). Patients with a lower abundance of Lachnoclostridium had better PFS (p = 0.048). Univariate (p = 0.017) and multivariate analysis (p = 0.040) showed that Lachnoclostridium was a predictor of PFS. Non-targeted metabolomics analysis revealed that Lachnoclostridium affects the efficacy of immunotherapy through the usnic acid.Conclusions: High abundance of Lachnoclostridium predicts poor prognosis in patients with NPC receiving immunotherapy.","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.27917","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Effective biomarkers for assessing anti-PD-1/PD-L1 therapy efficacy in patients with nasopharyngeal carcinoma (NPC) are still lacking. The human gut microbiota has been shown to influence clinical response to anti-PD-1/PD-L1 therapy in many cancers. However, the relationship between the gut microbiota and the efficacy of immunotherapy in patients with nasopharyngeal carcinoma has not been determined.

Methods: We conducted a prospective study in which fecal and blood samples from patients with NPC were subjected to 16S rDNA sequencing and survival analysis. To investigate potential differences in the gut microbiome between these groups and to identify potential biomarkers indicative of immunotherapy efficacy, patients were categorized into two groups according to their clinical response to immunotherapy, the responder group (R group) and the non-responder group (NR group). Progression-free survival (PFS) between these subgroups was analyzed using Kaplan-Meier survival analysis with the log-rank test. Additionally, we performed univariate and multivariate analyses to evaluate prognostic factors. Finally, we carried out non-targeted metabolomics to examine the metabolic effects associated with the identified microbiome.

Results: Our 16S rDNA sequencing results showed that the abundance of Lachnoclostridium was higher in the NR group than in the R group (p = 0.003), and alpha diversity analysis showed that the abundance of microbiota in the NR group was higher than that in the R group (p = 0.050). Patients with a lower abundance of Lachnoclostridium had better PFS (p = 0.048). Univariate (p = 0.017) and multivariate analysis (p = 0.040) showed that Lachnoclostridium was a predictor of PFS. Non-targeted metabolomics analysis revealed that Lachnoclostridium affects the efficacy of immunotherapy through the usnic acid.

Conclusions: High abundance of Lachnoclostridium predicts poor prognosis in patients with NPC receiving immunotherapy.

查看原文本刊更多论文

拉氏菌肠道菌群与鼻咽癌的免疫疗法疗效有关。

背景：目前仍缺乏有效的生物标志物来评估鼻咽癌（NPC）患者的抗PD-1/PD-L1疗效。人类肠道微生物群已被证明会影响许多癌症患者对抗PD-1/PD-L1疗法的临床反应。然而，鼻咽癌患者肠道微生物群与免疫疗法疗效之间的关系尚未确定：我们进行了一项前瞻性研究，对鼻咽癌患者的粪便和血液样本进行了 16S rDNA 测序和生存分析。为了研究这些组别之间肠道微生物组的潜在差异，并确定表明免疫疗法疗效的潜在生物标志物，我们根据患者对免疫疗法的临床反应将其分为两组，即有反应组（R组）和无反应组（NR组）。我们使用 Kaplan-Meier 生存分析和对数秩检验分析了这些亚组之间的无进展生存期（PFS）。此外，我们还进行了单变量和多变量分析，以评估预后因素。最后，我们还进行了非靶向代谢组学研究，以考察与所发现的微生物组相关的代谢效应：我们的 16S rDNA 测序结果显示，NR 组 Lachnoclostridium 的丰度高于 R 组（p = 0.003），α 多样性分析表明，NR 组微生物群的丰度高于 R 组（p = 0.050）。Lachnoclostridium丰度较低的患者的PFS较好（p = 0.048）。单变量分析（p = 0.017）和多变量分析（p = 0.040）显示，Lachnoclostridium 是 PFS 的预测因子。非靶向代谢组学分析显示，Lachnoclostridium通过琥珀酸影响免疫疗法的疗效：结论：Lachnoclostridium的高丰度可预测接受免疫治疗的鼻咽癌患者的不良预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.